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Background
Soluble guanylate cyclase (sGC) stimulators demonstrate
smooth muscle relaxation and vasodilation via the nitric
oxide (NO)-sGC-cyclic guanosine monophosphate
(cGMP) pathway. A novel class of sGC stimulators, the
pyrazole-pyrimidines, was synthesized with the objective
of creating a potent, once-a-day (QD) oral treatment for
cardiovascular diseases. Several compounds from this class
were identified as potent stimulators of sGC in vitro
(EC50 = 40-287 nM). These compounds were evaluated in
pharmacokinetic (PK) and blood pressure pharmacody-
namics (PD) in vivo rat and dog models and were shown
to exhibit sustained compound exposure (Thalf = >7 hours
in preclinical species) after oral dosing, predicting QD
dosing in humans. Further, they significantly decreased
mean arterial blood pressure (MAP (≥ 10mmHg) after
oral dosing. The potential for sGC stimulators to work in
combination with reference antihypertensive therapies was
assessed in an in vivo PD assay in a spontaneous hyperten-
sive rat (SHR) model. Doses of losartan, atenolol, amlodi-
pine, and our sGC stimulators that induced an effect
(< 30mmHg) on MAP were chosen. IWP-121, a represen-
tative sGC stimulator, was shown to provide additional
MAP lowering effects when combined with losartan, ate-
nolol, or amlodipine, resulting in an increase in overall
blood pressure effects between 5-50%. By linking com-
pound concentration to blood pressure change for each
compound alone and in combination, we were able to
assess the PK/PD relationships for the individual and com-
bined effects.
Conclusion
sGC stimulators from the pyrazole-pyrimidine class
demonstrated potent effects in lowering blood pressure
in rats and dogs with a PK profile consistent with pre-
dicted once a day dosing in humans. Furthermore, sGC
stimulator(IWP-121) enhanced the blood pressure low-
ering effects of standard anti-hypertensive agents in the
rat and may provide opportunities for treating patients
with resistant hypertension.
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